Insparin Therapeutics

Insparin Therapeutics is a clinical-stage biotechnology company spun out of Texas Tech University that is developing first-in-class therapies for severe insulin resistance and related metabolic diseases. The company's core technology is based on the E4orf1 protein, derived from human adenovirus Ad36, which promotes glucose uptake through an insulin-independent pathway. By binding to the DLG1 protein and activating the Ras-PI3K signaling cascade, the lead candidate, Insparin, bypasses traditional insulin signaling to improve glycemic control. This novel mechanism of action is being targeted for conditions such as type 2 diabetes, lipodystrophy, and metabolic dysfunction-associated steatohepatitis (MASH). Currently in the preclinical stage, the company is advancing its lead program toward an Investigational New Drug (IND) application using nanoparticle-mediated delivery systems. Insparin Therapeutics aims to provide transformative treatment options for patients who have few effective alternatives due to severe insulin resistance.